Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364557 · ClinicalTrials.gov registry record · Phase 2
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
A Phase 2 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT02364557 is a Phase 2 study that has completed, run by NRG Oncology. The registered enrollment target is 129 participants.
The verdict
NCT02364557, a Phase 2 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and/or surgery in treating limited metastatic breast cancer.
Interventions
- PROCEDURE Surgery
- RADIATION Stereotactic Body Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2014-12-24 |
| Est. Completion | 2025-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02364557
The ClinicalTrials.gov registry entry for NCT02364557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT02364557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02364557 about?
NCT02364557 is a clinical study titled "Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival". This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are...
What is the current status of trial NCT02364557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2014-12-24. Estimated completion is 2025-09-04.
What interventions are being tested in trial NCT02364557?
The interventions under investigation include: Surgery (PROCEDURE), Stereotactic Body Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT02364557?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.